Zelluna appoints Dr. Namir Hassan

Zelluna Immunotherapy, a biotechnology company specializing in T-cell receptor (TCR) immunotherapies, has announced the appointment of Dr. Namir Hassan as chief scientific officer (CSO). 

ADVERTISEMENT

“Namir has gathered extensive scientific knowledge in immunology, and, specifically, T-cell receptor based therapies. His experience spans research through to translational development in biotech and pharma and he has led the growth of research organizations in oncology and infectious diseases. This experience has given him excellent scientific and multi-organizational perspectives,” said Miguel Forte, CEO, Zelluna Immunotherapy. “As a result, Namir will be a great addition to Zelluna’s senior management team, and will contribute excellent ‘field-acquired’ experience and leadership to the development of the Zelluna product portfolio.”

Dr. Hassan’s key initial responsibilities will be managing and planning the next stages of development for Zelluna’s existing products. He will also manage the building of Zelluna’s own research team and facilities. On a longer-term basis, he will lead research activities for the expansion of Zelluna’s portfolio with a focus on adoptive cell therapy for solid cancers. 

YOU DON`T WANT TO MISS ANYTHING?

Sign up for our newsletter!